上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688065 证券简称：凯赛生物 中国·上海 二〇二五年五月十六日 上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会 目 录 | 上海凯赛生物技术股份有限公司 | 2025 | 年第一次临时股东大会会议须知 2 | | --- | --- | --- | | 上海凯赛生物技术股份有限公司 | 2025 | 年第一次临时股东大会议程 4 | | 议案一：关于变更公司注册资本、修订《公司章程》的议案 5 | | | | 议案二：关于选举公司第二届董事会非独立董事候选人的议案 7 | | | 1 上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.cathaybiotech.com 上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事 ...

Core Viewpoint - The article emphasizes the importance of scaling and cost-effectiveness in the bio-manufacturing industry to compete with traditional manufacturing sectors, particularly the chemical industry, and to achieve carbon neutrality goals [6][10][12]. Group 1: Key Elements of Bio-Manufacturing - Bio-manufacturing is positioned as a manufacturing sector that aims to replace traditional industries, particularly chemicals and inorganic materials [6][10]. - The success of high-tech industries relies heavily on research and development investments, which must be supported by companies possessing core technological capabilities [6][7]. - Intellectual property protection is crucial for fostering innovation and ensuring that companies can profit from their research investments [8][9]. - The supply of raw materials is a significant challenge, as bio-manufacturing must find reliable and stable sources of biomass that do not compete with food supplies [9][10]. Group 2: Resource Factors - Current bio-manufacturing resources primarily include food crops and biomass, with high-energy raw materials like palm oil and soybeans being expensive [13][17]. - Corn is the main raw material for bio-manufacturing globally, but its use in China is limited due to population pressures [17][19]. - The industry faces challenges in utilizing agricultural waste effectively, with many attempts resulting in commercial failures [17][19]. Group 3: Cost Factors - Selecting the right projects is essential to minimize trial and error costs in bio-manufacturing [20][22]. - The bio-manufacturing industry must compete with fossil fuels, and the energy density of bio-based materials is inherently lower than that of traditional chemical products [21][22]. - The cost structure of bio-manufacturing in China is competitive due to lower labor and investment costs compared to the US and Europe [28][30]. Group 4: Market Factors - New bio-manufactured products face significant market entry challenges, including user risk perceptions and complex value chains [31][33]. - The competition is not only from peers but also from established fossil fuel industries, which dominate market standards and decision-making processes [37][38]. - There are negative perceptions about bio-manufacturing being small-scale and high-cost, which can hinder investment and market acceptance [38][40]. Group 5: Recommendations for Bio-Manufacturing in Hainan - Companies should consider competitive energy solutions and the availability of raw materials when establishing bio-manufacturing projects in Hainan [48][49]. - The government should facilitate market access for bio-manufactured products to encourage early adoption and create demonstration cases [49][50].

Core Viewpoint - The article discusses the establishment and growth of Hefei Hydrogen He, a joint venture focused on bio-based materials, highlighting its strategic partnerships and financial performance of its parent company, Kaisa Bio [1][5]. Company Overview - Hefei Hydrogen He was registered on April 9, 2025, in the Hefei area of the China (Anhui) Free Trade Pilot Zone, with a registered capital of 20 million RMB, where Kaisa Bio holds a 55% stake [1]. - The legal representative of Kaisa Bio is Zhang Hongguang, who has been the Vice President since August 2019 [2]. Shareholding Structure - Kaisa Bio holds 55% of Hefei Hydrogen He, contributing 11 million RMB, while 3P.COM Corporation from South Korea holds 45%, contributing 9 million RMB [3]. Strategic Partnerships - In January 2024, Kaisa Bio signed an agreement with 3P.COM to establish a joint venture focusing on thermoplastic bio-based polyamide composite materials for hydrogen storage and transportation, urban air mobility, and wind turbine blades [3]. - Kaisa Bio has also established several other companies, including a joint venture with Ningde Times and Calai Composites, focusing on bio-based composite materials for battery casings and automotive parts [4]. Financial Performance - Kaisa Bio reported a total revenue of 2.958 billion RMB for 2024, marking a year-on-year increase of 39.91%, and a net profit of 489 million RMB, up 33.41% from the previous year [5]. Product Capacity and Sales - Kaisa Bio's total production capacity for various bio-based materials reached nearly 300,000 tons by the end of 2024, with specific capacities as follows: - Bio-based long-chain dicarboxylic acid: 115,000 tons [6] - Bio-based pentamethylenediamine: 50,000 tons [7] - Bio-based polyamide: 100,000 tons [8] - Bio-based continuous fiber thermoplastic composite materials [9]. - The main revenue sources for 2024 were long-chain dicarboxylic acid products, generating 2.670 billion RMB, and bio-based polyamide products, generating 144 million RMB [9]. Application Expansion - In March 2024, Kaisa Bio signed a cooperation agreement with China Merchants Highway and China Merchants Jinling to establish a joint laboratory for bio-based new materials, aiming to enhance performance and reduce costs in highway and green energy materials [11]. - Kaisa Bio provided low-carbon, high-performance composite materials for Qingdao Honghu Aviation Technology's RAP-AT1 active temperature-controlled container, which has entered commercial use [12].

证券代码：688065 证券简称：凯赛生物 公告编号：2025-023 上海凯赛生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内根据 市场情况择机做出回购决策并予以实施，并根据回购股份事项进展情况及时履行信 息披露义务，敬请广大投资者注意投资风险。 一、回购股份的基本信息 2024 年 10 月 21 日，公司召开第二届第二十四次董事会会议，审议通过了 《关于以集中竞价交易方式回购公司股份的方案》，同意公司使用自有资金或自 筹资金以集中竞价交易方式回购公司股份，回购资金总额不低于人民币 1,000.00 万元（含），不超过人民币 2,000.00 万元（含），回购价格不超过 67 元/股 （含），回购期限自董事会审议通过本次回购方案之日起 12 个月内。具体内容详 见公司于 2024 年 10 月 22 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-023 上海凯赛生物技术股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份情况公告如下： 2025 年 4 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易方式 回购公司股份 230,366 股,占公司总股本 721,289,794 股的比例为 0.0319%。回购 成交的最高价为 53.40 元/股，最低价为 44.08 元/股，支付的资金总额为人民币 10,497,716.71 元（不含印花税、交易佣金等交易费用)。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2025 年 4 月 30 日，上海凯赛生物技术股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 230,366 股,占公司总股本 721,289,794 股的比例为 0.0319%。回购成交的最高 ...

公募基金方面，本期较上一期持股增加的公募基金共计1个，即格林碳中和主题混合A，持股增加占比 小幅上涨。本期较上一季度持股减少的公募基金共计6个，主要包括华夏上证科创板50成份ETF、易方 达上证科创板50ETF、博时上证科创板新材料ETF、南方上证科创板新材料ETF、招商中证商品指数基 金等，持股减少占比达0.49%。本期较上一季未再披露的公募基金共计161个，主要包括南方中证 500ETF、科创ETF、广发科创50ETF、科创板ETF、国联安科创ETF等。 2025年4月30日，凯赛生物(688065.SH)发布2025年第一季报。截至2025年4月30日，共有16个机构投资 者披露持有凯赛生物A股股份，合计持股量达5.13亿股，占凯赛生物总股本的71.17%。其中，前十大机 构投资者包括上海曜修生物技术合伙企业(有限合伙)、山西潞安矿业(集团)有限责任公司、Cathay Industrial Biotech Ltd.、山西科技创新城投资开发有限公司、HBM Healthcare Investments (Cayman) Ltd.、天津四通陇彤缘企业管理合伙企业(有限合伙)、四川天府银行股份有限公司营业部、 ...

Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Views - The company's Q1 2025 performance met expectations, with total revenue of 776 million yuan, a year-on-year increase of 13% and a quarter-on-quarter increase of 4%. The net profit attributable to the parent company was 137 million yuan, reflecting a year-on-year growth of 30% [6][7] - The long-chain dicarboxylic acid business is experiencing steady growth, particularly with the ramp-up of sebacic acid, which has enhanced profitability. The company has increased sales efforts and is expanding its market share in new products [6] - Significant progress has been made in promoting bio-based polyamide modified and continuous fiber composite materials, with commercial orders expected to materialize [6] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3,539 million yuan, with a year-on-year growth rate of 19.6%. The net profit attributable to the parent company is forecasted to be 648 million yuan, representing a growth rate of 32.4% [6][7] - The gross profit margin for Q1 2025 was 33.63%, showing an increase of 4.95 percentage points year-on-year and 5.22 percentage points quarter-on-quarter [6] - The company’s return on equity (ROE) is projected to improve from 0.8% in Q1 2025 to 5.4% by 2027 [6]

Core Viewpoint - The article highlights the financial performance of Kasei Biotech in Q1 2025, showcasing significant growth in revenue and net profit, primarily driven by the sales of long-chain dicarboxylic acids [2][4]. Financial Performance - Kasei Biotech reported a revenue of 776 million yuan in Q1 2025, representing a year-on-year increase of 13.3% [2][3]. - The net profit attributable to shareholders reached 137 million yuan, up 30.1% compared to the same period last year [2][3]. - The net profit after deducting non-recurring gains was 135 million yuan, reflecting a 31.4% increase year-on-year [2][3]. - Research and development expenses amounted to 60.55 million yuan, marking a 35.21% increase from the previous year [2][3]. Product and Market Insights - The growth in net profit is attributed to the increased sales volume and gross profit from the series of long-chain dicarboxylic acids [4]. - Long-chain dicarboxylic acids (LCDA) are gaining traction in various applications, including the production of high-performance materials and pharmaceuticals [5]. - Kasei Biotech is positioned as a leading global supplier of bio-manufactured long-chain dicarboxylic acids, capitalizing on the market shift from traditional chemical methods to more sustainable production [5]. Capacity and Future Outlook - Kasei Biotech has a production capacity of 115,000 tons per year for bio-manufactured long-chain dicarboxylic acids and other related products [7]. - The company has successfully ramped up production of new products, such as dodecanedioic acid, contributing to significant revenue growth [6].

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月26日，第三届中国（安徽）科交会专项活动——合成生物平台建设和科技招商专项活动在合肥举办。 在重大项目签约环节，合肥高新区管委会、芜湖三山经开区管委会等地方政府单位与上海凯赛生物、深圳华大基因等企业集中签约了"生物基复合材料新 能源结构件研发制造项目"等5项"双招双引"重点项目， 累计投资达11.8亿元 。 其中，芜湖市三山经开区与 福莱 明生物 签约" 重组胶原蛋白和类胶原蛋白产品研发产业化项目 "；合肥市庐阳区与 华大基因 农业 签约" 华大生物农业 应用研究院建设和科技成果产业化项目 "； 安徽科宝生物 与中科院合肥物质研究院合作签约" 名贵中药材体培牛黄及其关键原料胆红素生物制造产业化 核心技术攻关 "项目，合肥高新区与 凯赛生物 签约" 生物基复合材料新能源结构件研发制造项目 "。 此外，由中国科学技术大学副校长周丛照、安徽师范大学常务副校长熊宇杰等专家学者发起的 安徽省合成生物学会 （筹）组建启动仪式也在当天举行。 资料来源： 添加微信请备注 ...

Summary of Kaisa Biotech Conference Call Company Overview - Kaisa Biotech reported a profit increase of 33.41% in 2024, reaching 489 million yuan, with a non-recurring net profit growth of 51.6% to 465 million yuan. [2][3] - In Q1 2025, the company achieved record revenue of 776 million yuan, a year-on-year increase of 13.33%, and a net profit of 137 million yuan, up 30.11%. [2][3] Financial Performance - For 2024, Kaisa Biotech's total revenue was 2.958 billion yuan, a 39.91% increase year-on-year, with a gross profit of 924 million yuan, up 51.83%. [3] - As of the end of 2024, total assets were 19.021 billion yuan, a 1% increase from the beginning of the year, and net assets were 11.507 billion yuan, up 3.07%. [3] - R&D investment was 233 million yuan, accounting for 7.89% of revenue, a decrease of 1 percentage point year-on-year. [3] Industry Dynamics - Approximately 40% of Kaisa Biotech's revenue comes from overseas markets, with limited impact from the US-China trade war due to the nature of its products. [2][6] - The company is focusing on large-scale applications in the construction sector through collaboration with China Merchants Group, with pilot projects underway in six regions. [2][7] Strategic Partnerships - Kaisa Biotech formed a joint venture with CATL (Contemporary Amperex Technology Co., Limited) named Anhui Kaixian Times, expected to involve new energy battery technologies and materials development. [2][8] - Multiple projects in power batteries and energy storage systems are being validated, with partial production expected by the second half of 2025. [9] Product Development - The company is launching a 10,000-ton bio-based polyamide project, which began production at the end of 2024 and has started sales in 2025, receiving positive customer feedback. [2][12] - Bio-based polyamide is being developed for various applications, including vulcanizing agents and agricultural intermediates, with a focus on increasing market share domestically and internationally. [13] R&D and Innovation - Kaisa Biotech is investing in AI through a partnership with Molecular Heart to enhance R&D efficiency in biomanufacturing, focusing on protein structure prediction and metabolic pathway design. [4][23] - The company has over 20 years of experience in the industrialization of long-chain dicarboxylic acids, utilizing gene editing and AI tools to accelerate R&D and reduce costs. [4][26] Market Outlook - The demand for long-chain dicarboxylic acids remains stable, with ongoing development of new applications expected to positively impact future demand. [29] - The company is also expanding its production capacity for long-chain dicarboxylic acids and related products to meet market needs. [21][29] Additional Insights - The joint venture with China Merchants is progressing, with equipment procurement nearly complete and construction expected to be operational by the end of 2025. [11] - The company is actively working on industry standard certifications to facilitate the adoption of its new materials in various applications. [28]